#126 Fecal Microbial Transplants (FMT) Immunology and Clinical Updates

1.5 CE Total | 1.5 Pharm

Now with AMA PRA Cat-1 CME (ACCME) Credit!

This course will have AMA PRA Cat-1 CME (ACCME) credit for one (1) year after being recorded on April 15th, 2025. Renewal will be done through AANP.

Fecal Microbiota Transplantation (FMT) was first described in the Chinese literature when Li Shizhen treated gastrointestinal diseases with “fresh yellow soup” which contained raw fecal material. ‘During the World War II, German soldiers were treated in Africa with FMT for dysentery. In medical literature, Ben Eiseman, a surgeon from Colorado-USA, treated patients with pseudomembranous colitis using fecal enemas.’ Fecal Microbiota transplantation has gained popularity during the epidemic appearance of Clostridium difficile infection resistant to usual treatments. The FDA regulated human feces in 2013 as an approved drug for treating Clostridium difficile infection. In the years since 2013 FMT has been proposed for use outside C. difficile infection in other areas of immunology. The purpose of this CME is to give an overview of FMT for clinicians to be prepared to refer for FMT procedures in appropriate patients. [Quotes from PMID: 27453747]

Learning Objectives:

• Describe the pharmacology of FMT
• Define the approved FMT indications in the US
• Define proposed indications
• Describe methods of FMT clinical application

Outline:

1. Describe the pharmacology of FMT
2. Define the approved FMT indications in the US
3. Define proposed indications
4. Describe methods of FMT clinical application

Recorded webinars will be available on the website as new courses within 72 hours of being recorded.